AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KNOV 22 min read$TOVX

Theriva Biologics, Inc. (TOVX): Completion of Acquisition or Disposition of Assets

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. - Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along w

Original reporting
SEC EDGAR 8-K
Published Nov 2, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$TOVX
Neutral
high confidence
Mentioned
$TOVX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TOVXNeutralMed
01

Why it matters

The transaction provides immediate cash and future upside but removes a pipeline segment, likely pressuring the share price.

02

Market read

Primary disclosure of a material asset sale; relevant for biotech investors and analysts tracking Theriva's pipeline.

03

What to watch

Future partnership opportunities for Biossil may enhance the value of the sold assets.

Relevance 7/10Novelty 7/10Timing: today

Background

Theriva Biologics, a clinical‑stage biotech, announced the sale of its SYN‑004, SYN‑007, and SYN‑006 enzyme portfolio.

Company-level read

Ticker impact

$TOVXNeutralHigh confidence
Context

Theriva Biologics disclosed the sale of its antibiotic‑degrading enzyme portfolio to Biossil Labs, receiving $350k upfront and up to $91M in milestones.

Expected impact

potential modest downside as the market prices out the loss of the enzyme portfolio

Evidence & confidence

Asset sale reduces future revenue streams; cash infusion is small relative to market cap, so investors may view it as a negative catalyst.

Market effects

Sector

May signal consolidation in the microbiome‑protecting therapeutics space.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The cash and milestone potential could be viewed as a catalyst for a short‑term rally.

Key entities

  • Company
    Theriva Biologics, Inc.

    Seller of the antibiotic‑degrading enzyme portfolio.

  • Company
    Biossil Labs Inc.

    Buyer, AI‑native biopharma acquiring the portfolio.

Read at source← All news

Related articles

SEP 30
$TOVXHighAI 9/10

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Theriva™ Biologics (NYSE American: TOVX) announced the publication of VIRAGE Phase 2b trial results for VCN-01 in metastatic pancreatic cancer in Nature Medicine. The study showed improved survival and response rates when VCN-01 was combined with standard chemotherapy. Theriva is now evaluating more frequent dosing in the VIRAGE2 Phase 2a trial and exploring VCN-01 for pediatric retinoblastoma.

globenewswire.com2 min
AUG 11
$TOVXMed

Theriva Biologics, Inc. (TOVX): Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve tr

SEC EDGAR 8-K4 min
AUG 6
$TOVXMed

Theriva Biologics, Inc.: Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patient

Theriva Biologics (NYSE American: TOVX) said the first patient was dosed in its VIRAGE2 Phase 2a trial testing more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma with gemcitabine/nab-paclitaxel. Enrollment is expected to finish in H2 2026, with initial data in Q3 2027.

finanznachrichten.de4 min
JUL 7
$TOVXMedAI 8/10

Theriva Biologics, Inc.: Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) i

Theriva Biologics (NYSE American: TOVX) said Spain’s AEMPS authorized it to start the VIRAGE2 Phase 2a trial of zabilugene almadenorepvec (VCN-01) with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer. VIRAGE2 will test feasibility of at least 3 VCN-01 doses 2 months apart in 6 patients; primary endpoints are safety and VCN-01 viral genome levels.

finanznachrichten.de2 min